{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:26:11Z","timestamp":1761942371988,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1053\/j.seminhematol.2005.12.010","type":"journal-article","created":{"date-parts":[[2006,3,19]],"date-time":"2006-03-19T21:09:49Z","timestamp":1142802589000},"page":"S27-S34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S2","title":["Purine Analogues in Advanced T-Cell Lymphoid Malignancies"],"prefix":"10.1053","volume":"43","author":[{"given":"Razelle","family":"Kurzrock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2005.12.010_bib1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib2","series-title":"Hematology (Am Soc Hematol Educ Program)","first-page":"259","article-title":"T cell and NK cell lymphoproliferative disorders","author":"Greer","year":"2001"},{"issue":"suppl 5","key":"10.1053\/j.seminhematol.2005.12.010_bib3","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1093\/annonc\/9.suppl_5.S25","article-title":"World Health Organization Classification of lymphomas","volume":"9","author":"Jaffe","year":"1998","journal-title":"Ann Oncol"},{"issue":"suppl 3","key":"10.1053\/j.seminhematol.2005.12.010_bib4","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1080\/10428190310001623757","article-title":"Overview of cutaneous T-cell lymphoma","volume":"44","author":"Foss","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib5","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood.V88.7.2385.bloodjournal8872385","article-title":"Mycosis fungoides and Sezary syndrome","volume":"88","author":"Diamandidou","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib6","series-title":"Hematology (Am Soc Hematol Educ Program)","first-page":"263","article-title":"Lymphoma of the skin","author":"Connors","year":"2002"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib7","doi-asserted-by":"crossref","first-page":"372","DOI":"10.7326\/0003-4819-109-5-372","article-title":"Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups","volume":"109","author":"Sausville","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1023\/A:1008397323199","article-title":"Prognostic factors in Sezary syndrome","volume":"9","author":"Bernengo","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib9","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1200\/JCO.2000.18.15.2908","article-title":"Primary cutaneous T-cell lymphoma","volume":"18","author":"Siegel","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib10","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0889-8588(18)30061-3","article-title":"Chemotherapy for mycosis fungoides and the Sezary syndrome","volume":"9","author":"Rosen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib13","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0140-6736(72)92692-X","article-title":"Adenosine-deaminase deficiency and combined immunodeficiency syndrome","volume":"2","author":"Dissing","year":"1972","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib14","first-page":"13","article-title":"Purine nucleoside analogs in indolent non-Hodgkin\u2019s lymphoma","volume":"14","author":"Cabanillas","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib15","first-page":"1731","article-title":"Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes","volume":"2","author":"Sandoval","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1172\/JCI111710","article-title":"Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes","volume":"75","author":"Seto","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib17","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/jnci\/82.16.1353","article-title":"Activity of fludarabine monophosphate in patients with advanced mycosis fungoides","volume":"82","author":"Von Hoff","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib18","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archderm.1996.03890320128028","article-title":"Successful treatment of Sezary syndrome with lymphomatous transformation to large cell lymphoma with fludarabine phosphate","volume":"132","author":"Nikko","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib19","first-page":"66","article-title":"Fludarabine phosphate therapy in other lymphoid malignancies","volume":"17","author":"Kantarjian","year":"1990","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib20","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.1994.12.10.2051","article-title":"Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides\/Sezary syndrome","volume":"12","author":"Foss","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib21","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1365-2133.2001.04191.x","article-title":"A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma","volume":"144","author":"Scarisbrick","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib22","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood.V94.8.2836.420k35_2836_2843","article-title":"In vitro evaluation of fludarabine in combination with cyclophosphamide and\/or mitoxantrone in B-cell chronic lymphocytic leukemia","volume":"94","author":"Bellosillo","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2133.2004.05712.x","article-title":"Treatment of advanced mycosis fungoides\/Sezary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy","volume":"150","author":"Quaglino","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V57.3.406.406","article-title":"The biochemical and clinical consequences of 2\u2032-deoxycoformycin in refractory lymphoproliferative malignancy","volume":"57","author":"Grever","year":"1981","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood.V61.2.279.279","article-title":"An investigation of 2\u2032-deoxycoformycin in the treatment of cutaneous T-cell lymphoma","volume":"61","author":"Grever","year":"1983","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.1991.9.4.565","article-title":"Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease","volume":"9","author":"Cummings","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0305-7372(90)90050-P","article-title":"Pentostatin (2\u2032-deoxycoformycin) for the treatment of lymphoid neoplasms","volume":"17","author":"Ho","year":"1990","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib28","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1023\/A:1008377724139","article-title":"Pentostatin in T-cell malignancies\u2014A phase II trial of the EORTC Leukemia Cooperative Group","volume":"10","author":"Ho","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib29","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0190-9622(97)80279-4","article-title":"Pentostatin (2\u2032-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma","volume":"36","author":"Greiner","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib30","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.1985.3.9.1196","article-title":"Low-dose deoxycoformycin in lymphoid malignancy","volume":"3","author":"Grever","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib31","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of pentostatin in the treatment of T-cell malignancies","volume":"12","author":"Mercieca","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib32","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/bjc.1991.423","article-title":"Deoxycoformycin in the treatment of mature T-cell leukaemias","volume":"64","author":"Dearden","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib33","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","article-title":"Pentostatin therapy of T-cell lymphomas with cutaneous manifestations","volume":"17","author":"Kurzrock","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.11899","article-title":"Phase II study of pentostatin in advanced T-cell lymphoid malignancies","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/10428190500282019","article-title":"Refractory Hodgkin\u2019s lymphoma responds to pentostatin (2\u2032 deoxycoformycin)","volume":"47","author":"Braiteh","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib36","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.1992.10.12.1907","article-title":"Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides\/Sezary syndrome","volume":"10","author":"Foss","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V80.3.587.587","article-title":"2-Chlorodeoxyadenosine","volume":"80","author":"Saven","year":"1992","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib38","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V84.3.733.733","article-title":"2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders","volume":"84","author":"O\u2019Brien","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib39","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V87.3.906.bloodjournal873906","article-title":"Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma","volume":"87","author":"Kuzel","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.blre.2005.01.002","article-title":"Infections associated with purine analogs and monoclonal antibodies","volume":"19","author":"Ravandi","year":"2005","journal-title":"Blood Rev"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib41","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/cncr.20615","article-title":"A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies","volume":"101","author":"Tam","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1586\/14737140.5.1.39","article-title":"Alemtuzumab","volume":"5","author":"Ravandi","year":"2005","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib43","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.0902-4441.2004.00169.x","article-title":"Successful treatment of chemotherapy-refractory Sezary syndrome with alemtuzumab (Campath-1H)","volume":"72","author":"Gautschi","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib45","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib46","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD52 in normal and leukemic B and T cells","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.leukres.2005.05.008","article-title":"Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin","volume":"30","author":"Ravandi","year":"2006","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib49","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0889-8588(03)00109-6","article-title":"Cytokine therapy of cutaneous T-cell lymphoma","volume":"17","author":"Rook","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib50","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/archderm.1995.01690170076011","article-title":"High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma","volume":"131","author":"Marolleau","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib51","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","article-title":"Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma","volume":"98","author":"Piekarz","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.010_bib52","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood.V87.3.893.bloodjournal873893","article-title":"Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody","volume":"87","author":"Knox","year":"1996","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196305002672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196305002672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:16:52Z","timestamp":1758521812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196305002672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":52,"alternative-id":["S0037196305002672"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2005.12.010","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Purine Analogues in Advanced T-Cell Lymphoid Malignancies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2005.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}